bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.10.21.513286

T cell subsets in chronic hepatitis C patients genotype 4 who achieved SVR following DAAs Therapy

Abstract

BackgroundT cells are the primary effector cells that mediate viral clearance in spontaneous recovery from HCV infection and T cell dysfunction is a hallmark of progression to chronic HCV infection. Material and methodsThis study included 49 well charcterised HCV genotype 4-infected patients at Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt, who were enrolled to receive direct acting antiviral therapy for hepatitis C. Immuno-phenotyping was performed to assess the expression of multiple T cell lineage, activation and inhibitory receptors. This was done before treatment, during treatment, at end of treatment and one year after treatment. 50 patients were also enrolled as control. ResultsOur data showed, significant increase in the percentages of CD8+ cells as compared to control group. The percentages of PD-1 expression on the CD8+ T-cell population were signifecntly elevated in patients before treatment (p<0.001). Significant increase in Treg (CD4+CD25hFoxP3+) subsets was noticed in comparison with control pateints. The expression of the inhibitory and activated markers in CD8+ T-cells was markedly reduced but more obvios in exhausted cytotoxic T cells compared to baseline finding (p<0.001). exhausted (PD1+CD8+) T-cells from HCV+ individuals reduced markedly after 4 weeks of DAA therapy (by 3 folds, p <0.001). Intereatingly it started to increase gradually again at the end of treatment and after 1 year but the increase doesnt reach levels noticed in healthy control subjects. ConclusionUnderstanding the mechanisms of immune dysfunction and barriers to immune restoration after HCV cure will aid in better understanding of the remaining negative long-term health outcomes for HCV patients and the possibility of HCC development.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Shiha, G., Soliman, R., Hassan, A., Mikhail, N., Nabil, A., Saleh, L., Sayed, D., Eslam, M.. 2022-10-22. T cell subsets in chronic hepatitis C patients genotype 4 who achieved SVR following DAAs Therapy. https://doi.org/10.1101/2022.10.21.513286

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Common viral infections seed regionally distinct resident memory T cells in the human CNS

T cells persist in the central nervous system (CNS) and can drive both protection and neurological disease. How these cells are organized in humans and what they recognize is largely unknown. Here, we profiled CD8 T cells across anatomically distinct CNS regions, obtained through on-site autopsies and temporal lobe resection surgeries, using single-cell RNA sequencing, paired T cell receptor sequencing, and DNA-barcoded tetramers. Resident memory T cells (TRM) specific for Epstein-Barr virus, cytomegalovirus, influenza A, and SARS-CoV-2 were identified across CNS compartments. Anatomical location was the strongest correlate of TRM cell state, with leptomeningeal cells adopting a cytokine-poised TRM program, whereas brain TRM cells were transcriptionally restrained. Cells of the same clonotype spanned tissues yet adopted local transcriptional states. Viral specificity added another layer of TRM heterogeneity with GZMK/GZMA-expressing EBV-specific populations and interferon-stimulated gene signatures in SARS-CoV-2 and Influenza A-specific cells. The human CNS thus harbors regionally distinct CD8+ TRM shaped by common viral exposures.

immunology↗

A regulatory T cell signature provides a shared molecular basis for the therapeutic window of opportunity in rheumatic disease

Rheumatic diseases, including rheumatoid arthritis (RA), spondyloarthritis (SpA) and osteoarthritis (OA), show distinct phenotypes yet respond to overlapping therapies, implicating shared immune mechanisms. In the Transimmunom cohort, we profiled peripheral blood from 240 individuals (47 healthy, 44 OA, 91 RA, 58 SpA) across deep immunophenotyping, immunoproteomics and Treg-Teff transcriptomics. Single-layer analyses revealed broader Treg than Teff remodeling, along with a shared pattern of reduced activated Tregs and expanded Helios+ Tregs across all diseases, alongside a decrease in functional Treg subpopulations, including CTLA4+ and CD45RA- Tregs. In RA specifically, LAG3+ Tregs were also expanded. Combining omics layers outperformed single-layer approaches for disease classification. Among individual layers, Treg transcriptomes were most discriminative, and integration uncovered disease-specific programs. Unsupervised clustering identified a cross-disease cluster independent of activity, treatment and age, mapping to early disease (<= years) and dominated by a Treg dysfunction-associated program. These results provide a biological rationale for the therapeutic "window of opportunity" concept and duration-stratified Treg-directed trials.

immunology↗

Inhibitory Fc Receptor sets a time limit on macrophage response to IgG

Antibodies engage both activating Fc Receptors and the inhibitory receptor Fc{gamma}RIIB. Why macrophages need a dedicated inhibitory receptor rather than simply tuning activating receptor signaling is unclear. Using DNA-based chimeric receptors and in silico modeling, we independently controlled activating and inhibitory Fc Receptors. We found that Fc{gamma}RIIB imposed a time limit on macrophage phagocytosis and ERK signaling. The time limit is due to activating Fc Receptors converting PI(4,5)P2 to PI(3,4,5)P3, which is subsequently converted to PI(3,4)P2 by Fc{gamma}RIIB. This leads to a pulse of active signaling, which is sufficient for phagocytosis of small bacteria-sized targets but not phagocytosis of large targets and TNF secretion. Unlike engaging Fc{gamma}RIIB, reducing activating Fc Receptor signaling decreased initiation of phagocytosis, the speed of PI(3,4,5)P3 generation, and the amplitude of ERK signaling. Our results demonstrate that Fc{gamma}RIIB controls the duration of IgG signaling, while the activating Fc Receptors control sensitivity.

immunology↗